Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells.

ABSTRACT:

Background

Patients with triple negative breast cancer (TNBC) exhibit poor prognosis and are at high risk of tumour relapse, due to the resistance to chemotherapy. These aggressive phenotypes are in part attributed to the presence of breast cancer stem cells (BCSCs). Therefore, targeting BCSCs is a priority to overcoming chemotherapy failure in TNBCs.

Methods

We generated paclitaxel (pac)-resistant TNBC cells which displayed higher sphere forming potential and percentage of BCSC subpopulations compared to the parental cells. A screen with various kinase inhibitors revealed dasatinib, a Src kinase family inhibitor, as a potent suppressor of BCSC expansion/sphere formation in pac-resistant TNBC cells.

Results

We found dasatinib to block pac-induced BCSC enrichment and S

SUBMITTER: Tian J 

PROVIDER: S-EPMC6288167 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature